Trial record 1 of 1 for:    dr falk psc
Previous Study | Return to List | Next Study

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01755507
Recruitment Status : Completed
First Posted : December 24, 2012
Last Update Posted : August 3, 2016
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH